Intellia 13G/A: Vanguard Reports 0 Shares
Intellia Therapeutics Inc Schedule 13G/A amendment: The Vanguard Group reports 0 shares and 0% beneficial ownership of Common Stock following an internal realignment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Intellia Therapeutics Inc Schedule 13G/A amendment: The Vanguard Group reports 0 shares and 0% beneficial ownership of Common Stock following an internal realignment. The filing states that, effective with the realignment and in reliance on SEC Release No. 34-39538, certain Vanguard subsidiaries will report ownership separately and Vanguard no longer is deemed to beneficially own those subsidiary-held securities. The filing is dated 03/13/2026 with a signature on 03/27/2026.
Insights
Vanguard disaggregation leaves Intellia holdings reported separately; Vanguard itself reports zero ownership.
The Vanguard Group amended a Schedule 13G to show 0 shares and 0% ownership of Intellia common stock as of the amendment. The filing cites an internal realignment and reliance on SEC Release No. 34-39538 to justify separate reporting by subsidiaries.
This change is administrative: ownership is being disaggregated to subsidiaries rather than aggregated under the parent. Subsequent filings from Vanguard affiliates will show any continuing positions; timing and quantities for those affiliate reports are not provided in the excerpt.
AI-generated analysis. How Rhea-AI works. Not financial advice.